TAT-N15, a specific inhibitor of PIK3R3, can inhibit intestinal inflammation and is a new therapeutic target for IBD and CAC (Abdel-Aziz et al., 2014). This evidence concerns the gene PIK3R3 and inflammatory bowel disease.